⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909288 | 1.00 | — | — | |
| SCHEMBL5328 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL27871150 | 0.98 | KDM4E (0.42) | — | |
| Piperazine SCHEMBL28120340 | 0.98 | KDM4E (0.42) | — | |
| Hydrochloric Acid SCHEMBL27837986 | 0.98 | KDM4E (0.42) | — | |
| Acetic Acid SCHEMBL28060482 | 0.92 | KDM4E (0.38) | — | |
| SCHEMBL31714117 | 0.90 | KDM4E (0.46) | — | |
| SCHEMBL31714197 | 0.90 | KDM4E (0.46) | — | |
| SCHEMBL28095750 | 0.88 | KDM4E (0.36) | — | |
| Trifluoroacetic Acid SCHEMBL28194920 | 0.87 | KDM4E (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637702-B2 | Process for preparing substituted imidazo[1,5-α]pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-114196659-B | Amidase mutant, coding gene, engineering bacteria and application thereof | 浙江工业大学 | 2024-02-13 | — | — | CN | disclosed |
| US-20230175026-A1 | Process for the Preparation of a Chiral Piperazine-2-carboxylic Acid | HOFFMANN-LA ROCHE INC. (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115461333-A | Process for the preparation of chiral piperazine-2-carboxylic acid | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-114196659-A | Amidase mutant, coding gene, engineering bacterium and application thereof | 浙江工业大学 | 2022-03-18 | — | — | CN | disclosed |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | ERASCA, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-1824961-B1 | MELIBIOSE OPERON EXPRESSION SYSTEM | LONZA AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| US-8735099-B2 | Melibiose operon expression system | MORPHOSYS AG (DE) | 2014-05-27 | — | — | US | disclosed |
| CN-102639134-A | Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors | SYMPHONY EVOLUTION INC | 2012-08-15 | — | — | CN | disclosed |
| EP-2482817-A1 | METHODS OF TREATING ANEURYSMAL DILATATION, BLOOD VESSEL WALL WEAKNESS AND SPECIFICALLY ABDOMINAL AORTIC AND THORACIC ANEURYSM USING MATRIX METALLOPROTEASE-2 INHIBITORS | Symphony Evolution, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1511488-A2 | HUMAN ADAM-10 INHIBITORS | Exelixis, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003106381-A2 | HUMAN ADAM-10 INHIBITORS | EXELIXIS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| CN-1093125-C | Sulfamide-metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-23 | — | — | CN | disclosed |
| EP-1140909-A1 | NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039119-A1 | NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
| CN-1250445-A | Sulfamide-metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2000-04-12 | — | — | CN | disclosed |
| EP-0582164-B1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | BRISTOL MYERS SQUIBB CO (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5382584-A | Antiischemic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| CN-1085216-A | Have the diphenyl-oxazole, thiazole and the imdazole derivatives that suppress the adenosine resorption | BRISTOL MYERS SQUIBB CO (US) | 1994-04-13 | — | — | CN | disclosed |
| EP-0582164-A1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | Bristol-Myers Squibb Company (US) | 1994-02-09 | — | — | EP | disclosed |